Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study
Jingwen Ai, Yi Zhang, Haocheng Zhang, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 639-647
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 179
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 178
Acceptance of COVID‐19 booster vaccination based on the protection motivation theory: A cross‐sectional study in China
Fan Wu, Yue Yuan, Zhaomin Deng, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 9, pp. 4115-4124
Open Access | Times Cited: 60
Acceptance of COVID-19 Vaccine Booster Doses Using the Health Belief Model: A Cross-Sectional Study in Low-Middle- and High-Income Countries of the East Mediterranean Region
Ramy Mohamed Ghazy, Marwa Abdou, Salah Al Awaidy, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 19, pp. 12136-12136
Open Access | Times Cited: 42
Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine
Zhifei Chen, Fangqin Xie, Hairong Zhang, et al.
Frontiers in Public Health (2025) Vol. 13
Open Access | Times Cited: 1
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial
Xuanyi Wang, Syed Faisal Mahmood, Fang Jin, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 1910-1919
Open Access | Times Cited: 38
Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study)
Zoltán Vokó, Zoltán Kiss, György Surján, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
Haoyue Cheng, Zhicheng Peng, Shuting Si, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 798-798
Open Access | Times Cited: 31
Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease
Chao Wang, Linyi Chen, Qing‐Bin Lu, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 920-920
Open Access | Times Cited: 25
Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing
Renyang Tong, Lingjie Luo, Yichao Zhao, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 14
Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications, Efficacy, and Adverse Effects of Inactivated Whole-Virus COVID-19 Vaccines Sinopharm, CoronaVac, and Covaxin: An Observational Study
Sultan Ayoub Meo, Riham A. ElToukhy, Anusha Sultan Meo, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 826-826
Open Access | Times Cited: 14
Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
Jira Chansaenroj, Nungruthai Suntronwong, Sitthichai Kanokudom, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1071-1071
Open Access | Times Cited: 19
Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling
Jingwen Ai, Jingxin Guo, Haocheng Zhang, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 18
Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants
Guiqiang Wang, Kexin Zhao, Xiuli Zhao, et al.
Expert Review of Vaccines (2025)
Open Access
Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens
Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, et al.
International Journal of Infectious Diseases (2022) Vol. 126, pp. 64-72
Open Access | Times Cited: 15
IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China
Guang Zeng, Liumei Xu, Shuidong Feng, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 880-880
Open Access | Times Cited: 14
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up
Zafer Sezer, Shaikh Terkıs Islam Pavel, Ahmet İnal, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 140-140
Open Access | Times Cited: 2
Immunogenicity following two doses of BBIBP-CorV vaccine and a third booster dose with viral vector and Mrna COVID-19 vaccines against delta and omicron variants in prime immunized adults with two doses of BBIBP-CorV vaccine
Jira Chansaenroj, Nungruthai Suntronwong, Sitthichai Kanokudom, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 11
Immunodominant SARS‐CoV‐2‐specific CD4 + and CD8 + T‐cell responses elicited by inactivated vaccines in healthy adults
Jie Ning, Qinjin Wang, Ying Chen, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Open Access | Times Cited: 6
Antibody response to the third dose of inactivated COVID‐19 vaccine in people living with HIV (PLWH): A longitudinal cohort
Guang Zeng, Fei He, Xiaomin Zhang, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 5
Closed Access | Times Cited: 6
Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population
Javeria Aijaz, Shakir Hussain, Fouzia Naseer, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 692-692
Open Access | Times Cited: 10
The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults
Qinjin Wang, Jie Ning, Ying Chen, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 8
Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study
Gui-Ping Wen, Min Zhu, Lirong Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants
Tianhong Li, Kathy Qian Luo
International Journal of Biological Sciences (2022) Vol. 18, Iss. 12, pp. 4642-4647
Open Access | Times Cited: 7
Association of fat-soluble vitamins (A, D, and E) status with humoral immune response to COVID-19 inactivated vaccination
Yao Deng, Liting Huang, Peixin Liu, et al.
Frontiers in Nutrition (2023) Vol. 10
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top